IROREST TBSU 125mg Price

Overview

Welcome to Dwaey, specifically on IROREST TBSU 125mg Dispersible Tablets for Oral Suspension page.
This medicine contains an important and useful components, as it consists of Deferasirox.
IROREST TBSU 125mg is available in the market in concentration 125 mg/Tablet and in the form of Dispersible Tablets for Oral Suspension.

APOTEX INC. is the producer of IROREST TBSU 125mg and it is imported from CANADA, The most popular alternatives of IROREST TBSU 125mg are listed downward .

Mode Of Action

Deferasirox is an orally active chelator that is selective for iron (as Fe3+ ion). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. It is used in the management of chronic iron overload.

Indication

• Chronic iron overload.

Precaution

Monitor renal function and CBC before starting treatment and regularly during treatment; may need to reduce dose or stop treatment if serum creatinine levels are persistently elevated. May increase LFTs. Perform audiological and ophthamological tests before starting treatment and yrly thereafter. Pregnancy. Lactation: not known whether excreted in breast milk, use caution

Side Effects

• >10% Serum creatinine increase (dose related; 7-38%)
• Abdominal pain (21-28%)
• Nausea (11-23%)
• Vomiting (10-21%)
• Diarrhea (12-20%)
• Proteinuria (19%)
• Pyrexia (19%)
• Headache (16%)
• Cough (14%)
• Nasopharyngitis (13%)
• Pharyngolaryngeal pain (11%)
• Influenza (11%)
• Rash (8-11%) 1-10% Respiratory tract infection (10%)
• Bronchitis (9%)
• ALT increased (2-8%)
• Arthralgia
• back pain (6-7%)
• Acute tonsillitis (6%)
• Rhinitis (6%)
• Fatigue (6%)
• Ear infection (5%)
• Transaminitis (4%)
• Urticaria (4%) <1% Anaphylaxis
• Angioedema
• Cytopenias
• including agranulocytosis
• neutropenia and thrombocytopenia; leukocytoclastic vasculitis Potentially Fatal: Acute renal failure
• serious hypersensitivity reactions such as angioedema and anaphylaxis.

Contra indication

Hypersensitivity.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks